Home         Forums  

Go Back   Marrowforums > Bone Marrow Failure Diseases > News and Events
Register FAQ Search Today's Posts Mark Forums Read

News and Events News related to bone marrow failure diseases

Reply
 
Thread Tools Search this Thread
  #1  
Old Mon Jan 14, 2008, 04:25 PM
Marrowforums Marrowforums is offline
Marrowforums.org
 
Join Date: Jul 2006
Posts: 919
Pharmion Applies for Vidaza Approval in Europe

Pharmaceutical company Pharmion has submitted a European Marketing Authorization Application (MAA) for Vidaza, for the treatment of patients with high risk MDS in the European Union (EU).

The MAA, submitted to the European Medicines Agency (EMEA), was based in part on an international Phase 3 trial of 358 mostly high-risk MDS patients in the U.S., Europe, and Australia. Treatment with Vidaza was compared with a conventional care regimen (CCR) and found to improve overall survival. Approval in Europe will expand the availability of Vidaza for high risk MDS patients.

Vidaza is a demethylation agent used to treat MDS/RA (refractory anemia), MDS/RARS (refractory anemia with ringed sideroblasts), MDS/RAEB (refractory anemia with excess blasts), MDS/RAEB-T (refractory anemia with excess blasts in transformation), and chronic myelomonocytic leukemia (CMMoL).

From Pharmion's press release:
"Our study results presented late last year at the American Society of Hematology meeting confirm that Vidaza should be considered first-line therapy for patients with higher-risk MDS," said Pierre Fenaux, M.D., Professor of Hematology at the University of Paris, and Head, Department of Clinical Hematology, Hopital Avicenne, France, and principal investigator of the Phase 3 study. "Overall survival is the gold standard by which clinical benefit should be measured for patients, and these data demonstrate the tremendous benefit that Vidaza can provide these patients; this represents a significant advance in the treatment of MDS patients."
Intravenous (IV) administration of Vidaza (azacitidine) for treatment in the U.S. of all subtypes of MDS was approved by the FDA in January 2007.
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 08:01 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org